Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
June 1, 2026 8:30 AM EDTEdgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones
Transaction Creates Focused Cardiovascular Company with Enhanced Strategic ClarityÂ
Upfront Proceeds Expected to Fully Fund EDG-7500 Development Through Potential ApprovalÂ
On Track to Report 12-Week CIRRUS-HCM Part D Data in Q2 2026
BOULDER, Colo., June 1, 2026 /PRNewswire/ --Â Edgewise Therapeutics, Inc.... More
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
June 1, 2026 8:30 AM EDTAcquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. Transaction represents total value of up to $2.65 billion.
SURESNES, France, June 1, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it... More
